about the author

Lia DeGroot

ldegroot@endpointsnews.com

author articles

Em­ploy­ers cov­er­ing GLP-1s could dou­ble in 2024 as ques­tions over cov­er­age guardrails loom

Last year
Pharma
FDA+

Cal­i­for­nia gov­er­nor ve­toes bill to cap in­sulin prices at $35 per month

Last year
Pharma
FDA+

CBO analy­sis calls for more re­search in­to sav­ings po­ten­tial for obe­si­ty treat­ments

Last year
Pharma
FDA+

Rea­gan-Udall Foun­da­tion lays out meth­ods for FDA to com­bat mis­in­for­ma­tion

Last year
Pharma
FDA+

Slew of phar­ma in­dus­try play­ers form coali­tion to push back against an­titrust re­form

Last year
Pharma
FDA+

Fed­er­al judge de­nies Cham­ber of Com­merce's ef­fort to block IRA's Medicare drug price ne­go­ti­a­tion pro­vi­sions

Last year
Pharma
FDA+

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

Last year
FDA+

Fed­er­al gov­ern­ment shut­down watch: FDA and in­dus­try prep for like­ly clo­sure Oct. 1

Last year
Pharma
FDA+

Biden ad­min­is­tra­tion doles out $100M to re­search drug-re­sis­tant in­fec­tions

Last year
R&D

FDA+ roundup: Agency re­opens AI dis­cus­sion pa­per for com­ments amid two-day work­shop

Last year
AI
Pharma

Pfiz­er restarts pro­duc­tion at tor­na­do-hit plant, ex­pects sup­ply is­sues to per­sist in­to 2024

Last year
Manufacturing

CDC ad­vi­sors rec­om­mend Pfiz­er's ma­ter­nal RSV vac­cine in 11-1 vote

Last year
Pharma
FDA+

Boehringer In­gel­heim, Eli Lil­ly clinch new FDA ap­proval for block­buster Jar­diance to treat chron­ic kid­ney dis­ease

Last year
Pharma
FDA+

FDA ad­vi­sors unan­i­mous­ly re­ject Intar­ci­a's em­bat­tled type 2 di­a­betes treat­ment

Last year
Pharma
FDA+

FDA un­der­scores qual­i­ty, safe­ty con­cerns with Intar­cia’s di­a­betes treat­ment ahead of ad­comm

Last year
Pharma
FDA+

House law­mak­ers press CMS on mon­i­tor­ing re­bate in­for­ma­tion, tout PBM re­forms at hear­ing

Last year
Pharma
FDA+

CDER di­rec­tor urges man­u­fac­tur­ers to work with FDA to fix in­spec­tion is­sues be­fore shut­ting down

Last year
Pharma
FDA+

House De­moc­rats push back on Re­pub­li­cans’ drug short­age pro­pos­als dur­ing leg­isla­tive hear­ing

Last year
Pharma
FDA+

CDER chal­lenges On­copep­tides’ ap­peal over Pepax­to with­draw­al

Last year
Pharma
FDA+

CDC pan­el rec­om­mends up­dat­ed Covid boost­ers for peo­ple 6 months and old­er

Last year
Pharma
FDA+

FDA slaps CVS, Wal­greens and oth­ers with warn­ing let­ters for un­ap­proved eye treat­ments

Last year
Pharma
FDA+

FDA green­lights up­dat­ed Covid shots, mak­ing fall boost­er roll­out im­mi­nent

Last year
Pharma
FDA+

FDA main­tains Covid flex­i­bil­i­ties for IRB re­view of ex­pand­ed ac­cess drugs for in­di­vid­u­als

Last year
Pharma
FDA+

Medicare en­rollees paid far more for drugs than plan spon­sors did in 2021, GAO says

Last year
Pharma
FDA+
First page Previous page 67891011 Next page Last page
A service from the Financial Times